Xarelto has been linked to hundreds of deaths, and the U.S. Food and Drug Administration is now investigating the safety of this medication intended for patients with atrial fibrillation, prior blood clots or upcoming knee or shoulder replacement surgery. Xarelto is not the only available blood thinner, but unlike many of its competitors, Xarelto does not have a reversal agent or antidote. This means that doctors have no way to reverse the effects of Xarelto and stop a bleed with patients taking Xarelto.
The makers of Xarelto, Bayer and Janssen Pharmaceuticals, knew of the serious risks, including intracranial hemmorhage and death, associated with a blood thinner that lacked both a reversal agent and a way to monitor the effects of the drug on an individual. Even with this information, Bayer and Janssen decided to place profits before people and continued to market Xarelto as a safer and more convenient alternative to other blood thinners.
The attorneys at Schachter, Hendy & Johnson successfully pursued and settled similar cases involving Pradaxa, another blood thinner that lacked both a reversal agent and a way to monitor the effects of the drug. The nationwide settlement was $650 million.